NovaBay Pharmaceuticals News

NovaBay Pharmaceuticals, Inc., a clinical stage biopharmaceutical company creating a new class of anti-infectives for treating multi-drug resistant pathogens, announced today that effective immediately, its partner, Alcon Inc.

Main Category: Infectious Diseases / Bacteria / Viruses Also Included In: Dermatology Pharma Industry / Biotech Industry NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. , a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, today announced that the company has named Mark Anderson, Ph.D. as chief scientific officer, a new position for the company.

NovaBay Pharmaceuticals, Inc. , a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, announced today the company has received acceptance to deliver a poster presentation at the 47th Annual Meeting of the Infectious Diseases Society of ...

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

NovaBay Pharmaceuticals, Inc. , a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver two poster presentations at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco, CA.

EMERYVILLE,A Calif. A clinical stage biopharmaceutical company reported a 63.5% increase in license and collaboration revenue for second quarter.

NovaBay Pharmaceuticals Inc. hired Roy Wu as senior vice president for business development.

EMERYVILLE, Calif. & HUENENBERG, Switzerland - Alcon, Inc. and its partner, NovaBay Pharmaceuticals, Inc.